Tags

Type your tag names separated by a space and hit enter

Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Exp Clin Psychopharmacol. 2013 Aug; 21(4):294-302.EC

Abstract

This pilot study examined the efficacy of the N-type calcium channel blocker gabapentin to improve outcomes during a brief detoxification protocol with buprenorphine. Treatment-seeking opioid-dependent individuals were enrolled in a 5-week, double-blind, placebo-controlled trial examining the effects of gabapentin during a 10-day outpatient detoxification from buprenorphine. Participants were inducted onto buprenorphine sublingual tablets during Week 1, were randomized and inducted onto gabapentin or placebo during Week 2, underwent a 10-day buprenorphine taper during Weeks 3 and 4, and then were tapered off gabapentin/placebo during Week 5. Assessments included thrice-weekly opioid withdrawal scales, vitals, and urine drug screens. Twenty-four individuals (13 male; 17 Caucasian, 3 African American, 4 Latino; mean age 29.7 years) participated in the detoxification portion of the study (gabapentin, n = 11; placebo, n = 13). Baseline characteristics did not differ significantly between groups. Self-reported and observer-rated opioid withdrawal ratings were relatively low and did not differ between groups during the buprenorphine taper. Urine results showed a Drug × Time interaction, such that the probability of opioid-positive urines significantly decreased over time in the gabapentin versus placebo groups during Weeks 3 and 4 (OR = 0.73, p = .004). These results suggest that gabapentin reduces opioid use during a 10-day buprenorphine detoxification procedure.

Authors+Show Affiliations

Department of Psychiatry and Behavioral Sciences, University of Arkansas for Medical Sciences, Little Rock, AR, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23855333

Citation

Sanders, Nichole C., et al. "Randomized, Placebo-controlled Pilot Trial of Gabapentin During an Outpatient, Buprenorphine-assisted Detoxification Procedure." Experimental and Clinical Psychopharmacology, vol. 21, no. 4, 2013, pp. 294-302.
Sanders NC, Mancino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol. 2013;21(4):294-302.
Sanders, N. C., Mancino, M. J., Gentry, W. B., Guise, J. B., Bickel, W. K., Thostenson, J., & Oliveto, A. H. (2013). Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Experimental and Clinical Psychopharmacology, 21(4), 294-302. https://doi.org/10.1037/a0033724
Sanders NC, et al. Randomized, Placebo-controlled Pilot Trial of Gabapentin During an Outpatient, Buprenorphine-assisted Detoxification Procedure. Exp Clin Psychopharmacol. 2013;21(4):294-302. PubMed PMID: 23855333.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. AU - Sanders,Nichole C, AU - Mancino,Michael J, AU - Gentry,W Brooks, AU - Guise,J Benjamin, AU - Bickel,Warren K, AU - Thostenson,Jeff, AU - Oliveto,Alison H, Y1 - 2013/07/15/ PY - 2013/7/17/entrez PY - 2013/7/17/pubmed PY - 2014/3/13/medline SP - 294 EP - 302 JF - Experimental and clinical psychopharmacology JO - Exp Clin Psychopharmacol VL - 21 IS - 4 N2 - This pilot study examined the efficacy of the N-type calcium channel blocker gabapentin to improve outcomes during a brief detoxification protocol with buprenorphine. Treatment-seeking opioid-dependent individuals were enrolled in a 5-week, double-blind, placebo-controlled trial examining the effects of gabapentin during a 10-day outpatient detoxification from buprenorphine. Participants were inducted onto buprenorphine sublingual tablets during Week 1, were randomized and inducted onto gabapentin or placebo during Week 2, underwent a 10-day buprenorphine taper during Weeks 3 and 4, and then were tapered off gabapentin/placebo during Week 5. Assessments included thrice-weekly opioid withdrawal scales, vitals, and urine drug screens. Twenty-four individuals (13 male; 17 Caucasian, 3 African American, 4 Latino; mean age 29.7 years) participated in the detoxification portion of the study (gabapentin, n = 11; placebo, n = 13). Baseline characteristics did not differ significantly between groups. Self-reported and observer-rated opioid withdrawal ratings were relatively low and did not differ between groups during the buprenorphine taper. Urine results showed a Drug × Time interaction, such that the probability of opioid-positive urines significantly decreased over time in the gabapentin versus placebo groups during Weeks 3 and 4 (OR = 0.73, p = .004). These results suggest that gabapentin reduces opioid use during a 10-day buprenorphine detoxification procedure. SN - 1936-2293 UR - https://www.unboundmedicine.com/medline/citation/23855333/Randomized_placebo_controlled_pilot_trial_of_gabapentin_during_an_outpatient_buprenorphine_assisted_detoxification_procedure_ L2 - http://content.apa.org/journals/pha/21/4/294 DB - PRIME DP - Unbound Medicine ER -